Complete Resolution of Localized Granuloma Annulare with Oral Abrocitinib
Main Article Content
Keywords
granuloma annulare, abrocitinib, jak inhibitor
Abstract
Granuloma annulare (GA) is an inflammatory granulomatous skin reaction with varied clinical presentations that preferentially affects women. Currently, treatments for granuloma annulare include topical or intralesional corticosteroids for localized disease and antibiotics, hydroxychloroquine, methotrexate, TNF-a inhibitors, pentoxifylline, and phototherapy for widespread disease. A treatment challenge to this approach is the lack of effective options for localized disease. We describe complete resolution of localized granuloma annulare with oral abrocitinib.
References
2. Min MS, Wu J, He H, et al. Granuloma annulare skin profile shows activation of T-helper cell type 1, T-helper cell type 2, and Janus kinase pathways. J Am Acad Dermatol. 2020;83(1):63-70. doi:10.1016/j.jaad.2019.12.028
3. Joshi TP, Duvic M. Granuloma Annulare: An Updated Review of Epidemiology, Pathogenesis, and Treatment Options. Am J Clin Dermatol. 2022;23(1):37-50. doi:10.1007/s40257-021-00636-1
4. Wang A, Rahman NT, McGeary MK, et al. Treatment of granuloma annulare and suppression of proinflammatory cytokine activity with tofacitinib. Journal of Allergy and Clinical Immunology. 2021;147(5):1795-1809. doi:10.1016/j.jaci.2020.10.012
5. Damsky W, Thakral D, McGeary MK, Leventhal J, Galan A, King B. Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare. Journal of the American Academy of Dermatology. 2020;82(3):612-621. doi:10.1016/j.jaad.2019.05.098
6. Perche PO, Cook MK, Feldman SR. Abrocitinib: A New FDA-Approved Drug for Moderate-to-Severe Atopic Dermatitis. Ann Pharmacother. 2023;57(1):86-98. doi:10.1177/10600280221096713
7. Damsky W. JAK1 Inhibition in Granuloma Annulare: An Opportunity for Pathogenesis Directed Therapy. clinicaltrials.gov; 2024. Accessed February 25, 2025. https://clinicaltrials.gov/study/NCT05650736
8. Liu W, Chen W, Tian X, et al. Oral abrocitinib in the treatment of granuloma annulare: a case report. Journal of Dermatological Treatment. 2024;35(1):2313090. doi:10.1080/09546634.2024.2313090
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.